Control Bionics (ASX: CBL) registers NeuroStrip with US FDA as commercial execution becomes the next test
Read More Pharma Industry News How Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia patients Find out how Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia, transforming treatment and investor sentiment alike. bySoujanya RaviOctober 24, 2025